Akebia Therapeutics Inc
NASDAQ:AKBA
Akebia Therapeutics Inc
Revenue
Akebia Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Akebia Therapeutics Inc
NASDAQ:AKBA
|
Revenue
$194.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Akebia Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Akebia Therapeutics Inc
Breakdown by Segments
Akebia Therapeutics Inc
Total Revenue:
194.6m
USD
|
Product Revenue, Net:
170.3m
USD
|
License, Collaboration And Other Revenue:
24.3m
USD
|
See Also
What is Akebia Therapeutics Inc's Revenue?
Revenue
194.6m
USD
Based on the financial report for Dec 31, 2023, Akebia Therapeutics Inc's Revenue amounts to 194.6m USD.
What is Akebia Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
-1%
Over the last year, the Revenue growth was -33%. The average annual Revenue growth rates for Akebia Therapeutics Inc have been -13% over the past three years , -1% over the past five years .